布地奈德联合阿奇霉素治疗支气管哮喘的疗效分析  

Analysis of therapeutic effect of budesonide combined with azithromycin in the treatment of bronchial asthma

作　　者：严国美 周伟 甘景帆 YAN Guo-mei;ZHOU Wei;GAN Jing-fan(Shenzhen Guangming District People's Hospital,Shenzhen 518106,China)

机构地区：[1]深圳市光明区人民医院,518106

出　　处：《中国实用医药》2025年第1期92-94,共3页China Practical Medicine

摘　　要：目的本文就布地奈德联合阿奇霉素对支气管哮喘患者的临床治疗效果进行探讨。方法选取86例支气管哮喘患者作为研究对象,随机分为对照组和观察组,每组43例。对照组应用布地奈德进行治疗,观察组应用布地奈德联合阿奇霉素进行治疗。对比两组患者临床疗效、肺功能指标、用药不良反应发生情况。结果观察组患者的临床总有效率为97.67%,显著高于对照组的76.74%(P<0.05)。治疗1周后,观察组患者的第1秒用力呼气容积(FEV1)、第1秒用力呼气容积占用力肺活量的百分比(FEV1/FVC)分别为(2.32±0.31)L、(78.24±9.41)%,均显著高于对照组的(2.05±0.24)L、(72.51±10.31)%(P<0.05)。观察组患者用药不良反应发生率11.63%明显低于对照组的30.23%(P<0.05)。结论在对支气管哮喘患者进行临床治疗时,通过布地奈德联合阿奇霉素的方式能够促进临床疗效进一步提高,改善患者的肺功能指标,提高用药安全性,值得在临床上应用推广。Objective To explore the clinical effect of budesonide combined with azithromycin in the treatment of bronchial asthma.Methods A total of 86 patients with bronchial asthma were selected as the study subjects,and randomly divided into a control group and an observation group,with 43 patients in each group.The control group was treated with budesonide,and the observation group was treated with budesonide combined with azithromycin.The clinical therapeutic effects,pulmonary function indexes,and occurrence of adverse drug reactions of the two groups were compared.Results The total clinical effective rate of the observation group was 97.67%,which was significantly higher than 76.74%of the control group(P<0.05).After 1 week of treatment,the forced expiratory volume in one second(FEV1)and the ratio of FEV1 to forced vital capacity(FEV1/FVC)in the observation group were(2.32±0.31)L and(78.24±9.41)%,which were significantly higher than(2.05±0.24)L and(72.51±10.31)%in the control group(P<0.05).The incidence of adverse drug reactions in the observation group was 11.63%,which was significantly lower than 30.23%in the control group(P<0.05).Conclusion In the clinical treatment of patients with bronchial asthma,budesonide combined with azithromycin can promote the further improvement of clinical therapeutic effect,improve the pulmonary function indexes of patients,and improve clinical drug safety,so it is worthy of clinical application and promotion.

关 键 词：布地奈德 阿奇霉素 支气管哮喘 疗效 

分 类 号：R562.25[医药卫生—呼吸系统]